Iovance Biotherapeutics (NASDAQ:IOVA) Shares Down 13.1% – Time to Sell?

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)’s stock price was down 13.1% during mid-day trading on Friday. The stock traded as low as $8.38 and last traded at $8.3110. 5,355,585 shares were traded during trading, a decline of 66% from the average session volume of 15,649,962 shares. The stock had previously closed at $9.56.

Trending Headlines about Iovance Biotherapeutics

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Iovance reported a 24.6% objective response rate among 69 patients with previously treated non-squamous mNSCLC. The KRAS wild-type subgroup posted a 43.3% response rate, while a novel biomarker-enriched subgroup reached 59.1%, supporting a precision-medicine approach. Iovance Reports Updated IOV-LUN-202 Results
• Positive Sentiment: Cohorts 1 and 2 are completing enrollment and are expected to support a supplemental Biologics License Application for lifileucel in non-squamous mNSCLC in 2027. Iovance also plans to begin enrollment in November for POSITILITY, a biomarker-enriched study with registrational intent. Iovance Lung Cancer Trial Update
• Positive Sentiment: Earlier melanoma and sarcoma findings reinforced investor interest in lifileucel’s potential beyond its current advanced-melanoma indication, including a reported 50% response rate in refractory undifferentiated pleomorphic sarcoma and liposarcoma. Lifileucel Shows 50% Response Rate
• Neutral Sentiment: Unusually heavy call-option buying and expectations for an earnings beat reflected speculative optimism, but these signals do not establish durable demand or clinical success. Iovance Earnings Expectations
• Negative Sentiment: The market reaction turned sharply negative after the updated lung-cancer readout. Investors appeared concerned that the 24.6% overall response rate was less compelling than the biomarker-selected results and that the 11.4% response rate in KRAS-mutant disease limits the addressable population, increasing regulatory and execution risk. Iovance Stock Reaction to Updated Lung Cancer Data

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. Mizuho upped their price objective on shares of Iovance Biotherapeutics from $10.00 to $11.00 and gave the company an “outperform” rating in a report on Tuesday, August 18th. Zacks Research upgraded Iovance Biotherapeutics from a “hold” rating to a “strong-buy” rating in a report on Monday. Citizens Jmp lifted their target price on shares of Iovance Biotherapeutics from $5.00 to $8.00 and gave the company a “market outperform” rating in a research note on Friday, August 7th. HC Wainwright upped their target price on shares of Iovance Biotherapeutics from $9.00 to $20.00 and gave the company a “buy” rating in a research note on Tuesday, September 29th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Iovance Biotherapeutics in a research report on Tuesday, September 29th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $13.20.

Iovance Biotherapeutics Price Performance

The stock’s fifty day simple moving average is $11.38 and its 200-day simple moving average is $5.79. The firm has a market cap of $3.90 billion, a PE ratio of -11.69 and a beta of 0.76.

Iovance Biotherapeutics (NASDAQ:IOVA) last posted its earnings results on Thursday, August 6th. The biotechnology company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.02. The firm had revenue of $99.31 million for the quarter, compared to analysts’ expectations of $87.83 million. Iovance Biotherapeutics had a negative return on equity of 40.51% and a negative net margin of 89.11%. The company’s quarterly revenue was up 65.7% on a year-over-year basis. During the same period last year, the firm earned ($0.33) EPS. Analysts expect that Iovance Biotherapeutics, Inc. will post -0.45 earnings per share for the current year.

Institutional Trading of Iovance Biotherapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Rice Hall James & Associates LLC acquired a new stake in shares of Iovance Biotherapeutics in the 2nd quarter worth approximately $6,406,000. Hennion & Walsh Asset Management Inc. grew its stake in shares of Iovance Biotherapeutics by 100.0% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 818,913 shares of the biotechnology company’s stock valued at $3,407,000 after acquiring an additional 409,449 shares in the last quarter. GSA Capital Partners LLP bought a new position in Iovance Biotherapeutics during the 2nd quarter worth approximately $2,726,000. Wellington Management Group LLP bought a new position in Iovance Biotherapeutics in the 2nd quarter worth about $531,000. Finally, Palo Alto Investors LP bought a new position in Iovance Biotherapeutics during the 2nd quarter valued at $22,032,229. 77.03% of the stock is owned by hedge funds and other institutional investors.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc (NASDAQ: IOVA) is a biotechnology company focused on developing and commercializing personalized cell therapies for patients with cancer. Its technology is based on tumor-infiltrating lymphocytes (TILs), immune cells collected from a patient’s tumor, expanded outside the body, and reinfused to help attack cancer cells.

The company’s lead product, Amtagvi (lifileucel), is an autologous TIL therapy approved in the United States for certain adults with unresectable or metastatic melanoma that has progressed following prior treatment.